Background & Aims Inhibitors of Janus kinases (JAKs) are being developed for treatment of
inflammatory bowel diseases and other immune-mediated diseases. Tofacitinib is effective …

Background The burden of herpes zoster (HZ) is significant worldwide, with millions affected
and the incidence rising. Current literature has identified some risk factors for this disease; …

Objective To systematically review studies examining risk factors for herpes zoster (HZ).
Methods We performed a literature search using PubMed, EMBASE, and Web of Science for …

Zusammenfassung Zum Erreichen eines optimalen Schutzes vor impfpräventablen
Erkrankungen werden im Folgenden Anwendungshinweise für die von der STIKO …

Objective: To assess the efficacy and safety profiles of different dosing regimens of
tofacitinib, baricitinib, and upadacitinib, novel selective oral Janus activated kinase …

Objective To compare event and incidence rates of herpes zoster (HZ), also known as
shingles, in patients with rheumatoid arthritis under treatment with conventional synthetic …

Increased risk of herpes zoster (HZ) has been observed in patients with immune-mediated
diseases, including rheumatoid arthritis (RA), psoriasis (PsO), and inflammatory bowel …

Janus kinase (JAK) inhibitors have been recently approved by the FDA and are widely used
in the treatment of patients with atopic dermatitis. However, a comprehensive safety profile of …

Compared with the general population, older adults with immune senescence and
individuals who are immunocompromised (IC) due to disease or immunosuppressive …

Background Herpes zoster (HZ) incidence is linked to immunosuppression. Patients with
psoriasis or psoriatic arthritis (PsA) on systemic therapy might be at an increased risk for HZ …